Clinical Trial Update: Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating monotherapy and combination therapy with sitaxsentan for pulmonary arterial hypertension; study terminated with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• SILDENAFIL (SILDENAFIL)
• Sitaxsentan (sitaxsentan)

Snippet

Sponsor: Pfizer | Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2012-02-20